Clinical meaning
Pancreatic ductal adenocarcinoma (PDAC) arises from the epithelial cells lining the pancreatic ducts through a stepwise progression of precursor lesions called pancreatic intraepithelial neoplasia (PanIN). PanIN-1 involves telomere shortening and activating mutations in the KRAS oncogene (present in >90% of PDAC), which drives constitutive activation of the RAS-RAF-MEK-ERK signaling cascade promoting uncontrolled cell proliferation. PanIN-2 acquires inactivation of the CDKN2A/p16 tumor suppressor (eliminating cell cycle checkpoint control), while PanIN-3 (carcinoma in situ) accumulates loss of TP53 (disabling DNA damage response and apoptosis) and SMAD4/DPC4 (disrupting TGF-beta growth inhibition signaling). The tumor microenvironment is uniquely hostile: PDAC is characterized by dense desmoplastic stroma (comprising up to 80% of tumor mass) produced by pancreatic stellate cells, which creates a hypovascular, hypoxic environment that impedes drug delivery and promotes chemoresistance. This desmoplasia also creates intense interstitial pressure that collapses blood vessels, explaining why PDAC is poorly enhanced on standard CT and requires pancreatic protocol triple-phase imaging for detection. Head tumors (60-70%) compress the common bile duct early, producing painless obstructive jaundice (Courvoisier sign — a palpable nontender gallbladder), while body/tail tumors present late with epigastric pain and weight loss because they lack proximity to the bile duct. CA 19-9 is a sialylated Lewis blood group antigen shed by pancreatic cancer cells; it is NOT a screening marker due to limited sensitivity and specificity but is valuable for monitoring treatment response and detecting recurrence. Lewis antigen-negative individuals (5-10% of the population) cannot produce CA 19-9 regardless of tumor burden, producing false negatives. PDAC also destroys islet cells, explaining why new-onset diabetes after age 50 may precede cancer diagnosis by 1-3 years — an important clinical red flag.